Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lethal Congenital Contracture Syndrome 2 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Nivolumab 19pembrolizumab 17Ipilimumab 13Specimen Handling 12Magnetic Resonance Spectroscopy 7CTLA-4 Antigen 6binimetinib 5Opdualag 5trametinib 4relatlimab 4dabrafenib 3Standard of Care 3Paclitaxel 3Introns 3Interferon alpha-2 3Gemcitabine 3Blood Specimen Collection 3ulixertinib 2sargramostim 2lenvatinib 2fludarabine phosphate 2fludarabine 2encorafenib 2capivasertib 2cabozantinib 2atezolizumab 2aldesleukin 2X-Rays 2Taxes 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Itraconazole × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡